McKenna, Jeffrey M.

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2018) · Cell Reports

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 451

Harnessing the anti-cancer natural product nimbolide for targeted protein degradation

Spradlin, J. N., Hu, X., Ward, C. C., Brittain, S. M., Jones, M. D., Ou, L., To, M., Proudfoot, A., Ornelas, E., Woldegiorgis, M., et al. (2019) · Nature Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 432

Deubiquitinase-targeting chimeras for targeted protein stabilization

Henning, N. J., Boike, L., Spradlin, J. N., Ward, C. C., Liu, G., Zhang, E., Belcher, B. P., Brittain, S. M., Hesse, M. J., Dovala, D., et al. (2022) · Nature Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 344

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

Ward, C. C., Kleinman, J. I., Brittain, S. M., Lee, P. S., Chung, C. Y. S., Kim, K., Petri, Y., Thomas, J. R., Tallarico, J. A., McKenna, J. M., et al. (2019) · ACS Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 336

Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications

Henning, N. J., Manford, A. G., Spradlin, J. N., Brittain, S. M., Zhang, E., McKenna, J. M., Tallarico, J. A., Schirle, M., Rape, M., & Nomura, D. K. (2022) · Journal of the American Chemical Society

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 221

Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function

Luo, M., Spradlin, J. N., Boike, L., Tong, B., Brittain, S. M., McKenna, J. M., Tallarico, J. A., Schirle, M., Maimone, T. J., & Nomura, D. K. (2021) · Cell Chemical Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 186

Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC

Boike, L., Cioffi, A. G., Majewski, F. C., Co, J., Henning, N. J., Jones, M. D., Liu, G., McKenna, J. M., Tallarico, J. A., Schirle, M., et al. (2021) · Cell Chemical Biology

Protein Degradation and InhibitorsClick Chemistry and Applications

Cited by 154

Manumycin polyketides act as molecular glues between UBR7 and P53

Isobe, Y., Okumura, M., McGregor, L. M., Brittain, S. M., Jones, M. D., Liang, X., White, R., Forrester, W., McKenna, J. M., Tallarico, J. A., et al. (2020) · Nature Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 124

A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL

Tong, B., Spradlin, J. N., Novaes, L. F. T., Zhang, E., Hu, X., Moeller, M., Brittain, S. M., McGregor, L. M., McKenna, J. M., Tallarico, J. A., et al. (2020) · ACS Chemical Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 118

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2019) · Cell Reports

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 53

Sulfinyl Aziridines as Stereoselective Covalent Destabilizing Degraders of the Oncogenic Transcription Factor MYC

Rosen, H. T., Li, K., Stieger, C. E., Li, E. L., Currier, B., Brittain, S. M., Garcia, F. J., Beard, D. C., Jones, M. D., Haenni‐Holzinger, S., et al. (2025) · Angewandte Chemie International Edition

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 15